Engineered donor cells take aim at returning blood cancers
NCT ID NCT01087294
First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 23 times
Summary
This study tested a new treatment for people whose B-cell cancers (like lymphoma or leukemia) came back after a donor stem cell transplant. Researchers took immune cells from the original donor, modified them to better recognize and attack cancer cells, and gave them to 85 patients. The goal was to see if this approach is safe and can help control the cancer, though it is not expected to be a cure and may require ongoing management.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, B-CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
National Marrow Donor Program
Minneapolis, Minnesota, 55401, United States
Conditions
Explore the condition pages connected to this study.